MILAN, ITALY - Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on novel therapies for central and peripheral nervous system diseases, announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting held today. Notably, this included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. The motions for the extraordinary part of the meeting were not put to vote, as the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors, expressed gratitude to shareholders for their trust and welcomed the newly elected members. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support. This board refresh is significant as Newron advances its lead compound, evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia (TRS), currently in the global pivotal ENIGMA-TRS Phase III program.
The company has a strong track record in neuroscience, with its first marketed product, Xadago®/safinamide, approved for Parkinson's disease across multiple regions. For further details, visit Newron's website. The original release is available on NewMediaWire.
